Pharmacoeconomic Perspectives on Clinical Pharmacy Practice: Enhancing Cost Efficiency in Healthcare

Year : 2026 | Volume : 16 | 01 | Page :
    By

    Krinal A. Patel,

  • Nidhi K. Parmar,

  • Disha J. Nagdev,

  • Beauty A. Yadav,

  • Bisojeet R. Khandai,

  1. Student, Department of Pharmacy Practice, Maliba Pharmacy College, Uka Tarsadia University, Bardoli, Gujarat, India
  2. Student, Department of Pharmacy Practice, Maliba Pharmacy College, Uka Tarsadia University, Bardoli, Gujarat, India
  3. Student, Department of Pharmacy Practice, Maliba Pharmacy College, Uka Tarsadia University, Bardoli, Gujarat, India
  4. Student, Department of Pharmacy Practice, Maliba Pharmacy College, Uka Tarsadia University, Bardoli, Gujarat, India
  5. Student, Department of Pharmacy Practice, Maliba Pharmacy College, Uka Tarsadia University, Bardoli, Gujarat, India

Abstract

Pharmacoeconomics is an essential aspect of clinical pharmacy that determines the cost-effectiveness of drug treatment, which helps healthcare providers to allocate resources fully. This review discusses some of the notable pharmacoeconomic evaluation techniques, including Cost-Effectiveness Analysis (CEA), Cost-Utility Analysis (CUA), and Cost-Benefit Analysis (CBA), and their use in clinical decision-making. The paper also brings out the importance of clinical pharmacy intervention, such as Medication Therapy Management (MTM), patient counselling, and drug adherence interventions, in the efficiency of healthcare by lowering costs and improving patient outcomes. In addition to this, the review covers issues of regulatory complications, availability of data, and the controversy of the cost-benefit issue. In the future, the application of artificial intelligence and tailored medicine should be optimized, enhancing the application of pharmacoeconomic assessments. Pharmacoeconomics should be incorporated into the clinical pharmacy practice in order to develop cost-effective and sustainable healthcare systems.

Keywords: Pharmacoeconomics, clinical pharmacy, cost-effectiveness, Medication Therapy Management (MTM), personalized medicine, healthcare efficiency, and cost-benefit analysis.

How to cite this article:
Krinal A. Patel, Nidhi K. Parmar, Disha J. Nagdev, Beauty A. Yadav, Bisojeet R. Khandai. Pharmacoeconomic Perspectives on Clinical Pharmacy Practice: Enhancing Cost Efficiency in Healthcare. Research and Reviews: A Journal of Pharmacology. 2026; 16(01):-.
How to cite this URL:
Krinal A. Patel, Nidhi K. Parmar, Disha J. Nagdev, Beauty A. Yadav, Bisojeet R. Khandai. Pharmacoeconomic Perspectives on Clinical Pharmacy Practice: Enhancing Cost Efficiency in Healthcare. Research and Reviews: A Journal of Pharmacology. 2026; 16(01):-. Available from: https://journals.stmjournals.com/rrjop/article=2026/view=237359


References

  1. Mohiuddin¹ A. Pharmacoeconomics: The Cost of Health. Indian Journal of Medical Science. 2018;70(2):11-20.
  2. Alaklobi AAD, Alaklabi SM, Alkurbi ZA, Alqarni HM, Alqarni FM, Alqarni MA, et al. Pharmacoeconomics and Health Policy: Assessing the Cost-Effectiveness of Pharmaceutical Interventions and its Insinuations for Policy Decision-Making Strategy. Azerbaijan Pharmaceutical and Pharmacotherapy Journal. 2024;23:1-19.
  3. Walley T, Haycox A. Pharmacoeconomics: basic concepts and terminology. British journal of clinical pharmacology. 2003;43(4):343.
  4. Kulkarni U, Dalvi K, Moghe V, Deshmukh Y. Pharmacoeconomics: An emerging branch in health sciences for decision making. African Journal of Pharmacy and Pharmacology. 2009;3(8):362-7.
  5. Wertheimer AI, Rychlik R. Strategies in pharmacoeconomics and outcomes research: CRC Press; 2002.
  6. Thomas D, Hiligsmann M, John D, Al Ahdab OG, Li H. Pharmacoeconomic analyses and modeling.  Clinical pharmacy education, practice and research: Elsevier; 2019. p. 261-75.
  7. Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd III GD, Dupuy DE, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. Journal of Vascular and Interventional Radiology. 2009;20(7):S377-S90.
  8. Rajan SK, Cottin V, Dhar R, Danoff S, Flaherty KR, Brown KK, et al. Progressive pulmonary fibrosis: an expert group consensus statement. European Respiratory Journal. 2023;61(3).
  9. Dao TD. Cost-benefit and cost-effectiveness analysis of drug therapy. American Journal of Hospital Pharmacy. 1985;42(4):791-802.
  10. Edlin R, Round J, Hulme C, McCabe C. Cost‐effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists. British journal of clinical pharmacology. 2010;70(3):350-5.
  11. Tonin FS, Aznar-Lou I, Pontinha VM, Pontarolo R, Fernandez-Llimos F. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. Pharmacy Practice (Granada). 2021;19(1).
  12. Wallerstedt SM, Bladh L, Ramsberg J. A cost-effectiveness analysis of an in-hospital clinical pharmacist service. BMJ open. 2012;2(1):e000329.
  13. Lonsdale DO, Guilding C, Koenig J, Okorie M, Sofat R, Maxwell S. Clinical pharmacology and prescribing education: An updated medical school curriculum from the British Pharmacological Society. British Journal of Clinical Pharmacology. 2026.
  14. Vijukumar A, Kosey S. UNLOCKING THE FULL POTENTIAL OF REAL-WORLD EVIDENCE IN PHARMACOECONOMIC ANALYSES: A FRAMEWORK FOR ADOPTION. Health Policy and Technology. 2026:101165.
  15. Kim JH, Sohn M, Woo J, Shin J, Han E. Digital Cognitive Behavioral Therapy for Chronic Insomnia in South Korea: Cost-Effectiveness Analysis Using Decision Tree and Markov Modeling Based on a Secondary Analysis of a Randomized Clinical Trial. JMIR mHealth and uHealth. 2026;14(1):e71750.
  16. Medina J, Sánchez-Covisa J, Nuevo J, Galvez-Fernandez M, García A, Pimentel B, et al. Shaping the Future of Evidence Generation: Real-World Data to Drive Healthcare Transformation and Patient-Centered Decisions: J. Medina et al. Pharmaceutical Medicine. 2026:1-12.
  17. Moghul M, Yi D, Croft F, Mutch F, Westaway E, Kinsella N, et al. A Cost-Analysis and Micro-Costing Study of the Man Van Project: Comparing Prostate-Specific Antigen Testing Via a Nurse-Led Mobile Service with Primary Care: M. Moghul et al. PharmacoEconomics-Open. 2026:1-12.
  18. Sanyal C, Watema‐Lord R, Xie F. Cost‐Utility of Pharmacist‐Led Deprescribing Interventions for Community‐Dwelling Older Adults: A Systematic Review. Journal of the American College of Clinical Pharmacy. 2026;9(2):e70166.
  19. Uyl-de Groot CA, Xander NS, Belleman T, Burger EA, Doeswijk R, Durand-Zaleski I, et al. Bridging Affordability and Sustainability of Health Innovations via Novel Pricing, Cost-effectiveness, and Reimbursement Models to Improve Patient Access: The ASCERTAIN Project. Health Policy and Technology. 2026:101155.
  20. Jabri W, Azoulay K, Jemjami S, Moustaid K. Optimization of quality costs in pharmacy: analysis, prioritization, and environmental perspectives. Euro-Mediterranean Journal for Environmental Integration. 2026;11(2):86.
  21. Gao H, Li L, Zhang H, Ma W, Wang Y. RAD‐SHIP—A New Model Called Rational Antibiotic Use‐Stewardship to Control Antimicrobial Use Intensity and Effectiveness in Hospitals. Journal of Clinical Pharmacy and Therapeutics. 2026;2026(1):4429079.
  22. Rakshith U. Digital Health Interventions by Clinical Pharmacists to Improve Medication Adherence: A Contemporary Review.
  23. Oliveira EM, Ferreira LC, Hattori WT. Optimizing Medication Use in Older Adults in Primary Care: A Systematic Review of The Effectiveness of Deprescribing Interventions. 2026.
  24. Versteeg J-W, Ollendorf D, Mantel-Teeuwisse AK, Goettsch WG, Leopold C. A Multi-Stakeholder Survey on Communicating Cost-Effectiveness Uncertainties to Stakeholders: A Case Study of ICER. Health Affairs Scholar. 2026:qxag009.
  25. Himmler S, Takano K, Nakagawa T, Herzog E, Günak MM, Peters S, et al. Cost-effectiveness of a transdiagnostic group exercise intervention for mental health in Germany (ImPuls trial): an economic evaluation study. The Lancet Psychiatry. 2026.
  26. Parkin D, Briggs A, Abangma G, Lloyd A, Devlin N. Uncertainty around Health State Values Used in Cost-Effectiveness Analysis: How It Arises and How to Deal with It. Medical Decision Making. 2026:0272989X251380556.
  27. Daoutakou M, Kintzios S, editors. The Role of Pharmacies in Providing Point-of-Care Services in the Era of Digital Health and Artificial Intelligence: An Updated Review of Technologies, Regulation and Socioeconomic Considerations. Healthcare; 2026: MDPI.
  28. Kaló Z, Petrova G, Németh B, Bonča PD, Delnoij D, Bennett A, et al. Transferability of Real World Evidence to Support HTA Recommendations in Lower Income European Countries. Health Science Reports. 2026;9(2):e71534.
  29. 29. Haerdtlein A, Bernartz K, Peter S, Lepenies LK, Puzhko S, Eberhardt Y, et al. General practitioner–pharmacist collaboration to enhance deprescribing of psychotropics, sedatives, and anticholinergics among older polypharmacy patients in primary care: study protocol of a cluster-randomized controlled trial (PARTNER). Therapeutic Advances in Drug Safety. 2026;17:20420986251400042.
Ahead of Print Subscription Review Article
Volume 16
01
Received 06/02/2026
Accepted 15/02/2026
Published 22/02/2026
Publication Time 16 Days
122

Login


My IP

PlumX Metrics